David A. Stamler
CEO, MD & DirectorDr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021 and serves as its Director since November 21, 2025 and is its Managing Director. He had been the Chief Medical Officer and Senior Vice President of Clinical Development at Alterity Therapeutics Limited since May 15, 2017. He served as the Chief Medical Officer at Auspex Pharmaceuticals, Inc. since January 2011 until 2015 when Teva acquired Auspex. He served as Chief Medical Officer and Senior Vice President of Xenoport, Inc. from July 2008 to November 19, 2010, where he led clinical development activities for the portfolio of CNS compounds. He served as Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc. since June 2005 until 2008, where he led clinical and non-clinical development activities and was responsible for the FDA approval of XenazineTM. From 2003 to 2005, he served as Senior Global Project Leader of Central Nervous System (CNS) Diseases of Fujisawa Pharmaceutical Company, where he led global development activities for two drugs to treat Alzheimer's Disease and a drug for acute stroke. He has clinical development experience. From 2003 to 2005, he also served as Vice President of Research and Development, Medical Sciences for its U.S. subsidiary, Fujisawa Healthcare, Inc. From 1997 to 2003, he served in positions of increasing responsibility for the Fujisawa Research Institute of America, Inc. and served as Medical Director and served as its Vice President from 2000 to 2003. At Abbott Laboratories, he served as Director of Clinical Research of Pharmaceutical Products at the International Division from 1995 to 1997. He began his career at Abbott Laboratories, where he served in various positions from 1993 to 1997. He served has been Member of Research & Development Advisory Board at Alterity Therapeutics Limited since June 2017. From 1993 to 1995, he served as an Associate Medical Director of Anti-infectives, with responsibility for Phase 1-4 trials in respiratory infection and H. pylori-associated gastrointestinal infection. He serves as a Founding Member of the American Society of Experimental Neuro Therapeutics (ASENT), a Member of the American Academy of Neurology and the American College of Physicians. He has authored publications in peer-reviewed scientific journals for CNS, gastrointestinal, respiratory and inflammatory diseases. Prior to joining Alterity, he served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries, from 2015 to 2017. He completed his Residency in Internal Medicine at Temple University Hospital as well as Fellowships in Infectious Diseases and Clinical Microbiology at the University of Pennsylvania. He is Board Certified in Internal Medicine and Infectious Diseases. He received his B.A. in Biology from University of Chicago and M.D. from the University of Chicago —The Pritzker School of Medicine.
Positions
- Company NameAlterity Therapeutics LimitedStock CodeATHEPositionCEO, MD & DirectorColleagues
- JBJulian BabarczyIndependent Non-Executive Chair
- AMAbby Macnish NivenCFO & Company Secretary
- RERudolph Emile TanziChief Scientific Advisor and Member of Research & Development Advisory Board
- SDSteven D. TargumChief Medical Advisor
- RCRobert ChernyHead of Research
- PAPeter Ashley MarksNon-Executive Independent Director
- ISIra ShoulsonChairman of Research & Development Advisory Board
